Clinical Trial Update: Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety study of EMD 72000 in combination with ECX chemotherapy for esophagogastric cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)
• EMD 72000
• Epirubicin (epirubicin)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Esophageal Cancer, Gastric Cancer | Phase 1 | Status: COMPLETED